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a b s t r a c t
Oxidative modiﬁcations in lipoproteins (LP), especially in low-density lipoproteins (LDL), are associated
with initiation and progression of atherosclerosis. The levels of a sub-fraction of LDL with oxidative char-
acteristics, named electronegative LDL [LDL(−)], minimally oxidized LDL, andminus LDL, are known to be
increased in subjects with familial hypercholesterolemia, hypertriglyceridemia, nonalcoholic steatohep-
atitis, diabetes mellitus, coronary artery disease, patients undergoing hemodialysis, and athletes after
aerobic exercise. In addition to the oxidative proﬁle, physical and biological characteristics of LDL(−)eywords:
lectronegative LDL
iomarker
mmune response
athophysiology
consist of nonenzymatic glycosylation, increased expression and activity of platelet-activating factor
acetylhydrolase (PAF-AH) and phospholipase A2 (PLA2), enriched NEFA content, hemoglobin and ApoB-
100 cross-linking, and increase in ApoC-III and ApoE in LDL. Herein, we summarize the state of the art
of the up-to-date body of knowledge on the possible origin and impact of LDL(−) in health and disease.
Further, the potential perspectives of using LDL(−) as a biomarker in conditions under metabolic stressxidative damage
ardiovascular disease
are also discussed.
© 2011 Elsevier Ireland Ltd. 
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. Introduction
Oxidative modiﬁcations in lipoproteins (LP), especially in low-
ensity lipoproteins (LDL), are associated with atherosclerosis and
peroxide present in cells, especially macrophages present in the
arterial wall), enzymes (such as lipoxygenases), and products of
myeloperoxidase. This exposure may lead to depletion of antiox-
Open access under the Elsevier OA license.any studies have detected oxidatively modiﬁed LDL particles in
umans [1–6], monkeys [7], and rabbits [8].
Oxidized LDL (oxLDL) results from exposure of LDL to a num-
er of oxidizing agents (such as superoxide anion and hydrogen
∗ Corresponding author at: Faculdade de Saúde Pública da USP, Av Dr Arnaldo,
15, 01246-904 São Paulo, SP, Brazil. Tel.: +55 11 3061 7865; fax: +55 11 3061 7130.
E-mail addresses: nagila@usp.br, nagila.damasceno@pq.cnpq.br
N.R.T. Damasceno).
021-9150 © 2011 Elsevier Ireland Ltd. 
oi:10.1016/j.atherosclerosis.2010.12.028
Open access under the Elsevier OA license.idant compounds and later oxidation of the lipid and protein
components of LDL particles [9]. Previously, Esterbauer et al. found
that oxLDL is an important atherogenic factor occurring in plasma,
arteries, and plaques of humans and experimental animals [10].
According to Toshima et al., lack of association with hypertension,
serum cholesterol, smoking, and sex suggested that oxLDL is an
independent risk factor for cardiovascular heart disease (CHD) [11].
Avogaro et al. described a sub-fraction of LDL with oxidized
characteristics that was named electronegative LDL [LDL(−)] [1].
Later, this particle was denominated as minimally oxidized LDL
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Table 1
Behavior of LDL(−) in disease and health conditions.
Study design Endpoint (LDL(−)
content)
References
Familial hypercholesterolemia
FH×NL ↑ FH [13,14,16]
FH× FH plus SIM (2 months) ↑ FH, basal [29]
FH× FH plus SIM (3 months) ↑ FH, basal [16]
FH× FH plus SIM (6 months) ↑ FH, basal [16]
FH× FH plus SIM or SIM+-tocopherol ↑ FH, basal [29]
Other dyslipidemias
HTG×NL ↑ HTG [13]
HC×NL ↑ HC [30]
Diabetes mellitus
DM2× control ↑ DM [18,20,22]
DM2 with MA× control ↑ DM, with MA [19]
DM2 with MA×DM2 without MA ↑ DM, with MA [19]
DM2×DM2 with acarbose ↑ DM, basal [31]
DM1 with poor GC× control ↑ DM [21]
DM1 with good GC× control ↑ DM [21]
DM1 with poor GC×DM1 with good GC ↑ DM, with poor GC [21]
Exercise
Athletes before AE× athletes after AE ↑ After [28]
Renal disease
HD× control ↑ HD [25]
HD×PD ↑ HD [26]
HD×HD plus -tocopherol ↑ HD, basal [32]
Other situations
ACS× control ↑ ACS [24]
SA× control ↑ SA [24]
CAD× control ↑ CAD [23]
Nonalcoholic SH× alcoholic SH ↑ Nonalcoholic SH [17]
ACS: acute coronary syndrome; AE: aerobic exercise; CAD: coronary artery dis-
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Table 2
Physicochemical properties, composition, and oxidative parameters of electroneg-
ative LDL in comparison with native LDL.
Characteristics Electronegative
LDL
References
Total cholesterol Higher [14–16,35]
Triglycerides Higher [14–16,21,22,35,36]
Phospholipids Lower [14]
Apo B Lower [14–16,21,22,35,36]
Apo E Higher [14,16,21,22,35,36]
Apo CIII Higher [14,16,21,22,35,36]
NEFA Higher [14–16,21,22,35,36]
PAF-AH activity Higher [15,21,22,36]
IL-8 Higher [16,35]
IL-6 Higher [27]
MCP-I Higher [16,35]
GM-CSF Higher [34]
GRO Higher [34]
GRO Higher [34]
Lysophosphatidylcholine Higher [35]
TBARS Higher [37]
Conjugated dienes Higher [7,37,38]
Alpha-tocopherol Lower [37]
Sialic acid Higher [14,38]
Lycopene Lower [22]
Lag phase Higher [14,16,21,22]
Afﬁnity to LDLr Lower [16]
Electrophoretic mobility Higher [6]
Loss of secondary structure of Apo B Higher [37]
Total PUFA Lower [7]
Total cholesterol Higher [14–16,35]
GM-CSF: granulocyte/monocyte colony-stimulating factor; GRO: growth-related
oncogene ; GRO: growth-related oncogene ; IL-6: interleukin-6; IL-8:
interleukin-8; LDLr: low-density lipoprotein receptor; MCP-I: monocyte chemotac-ase; DM: diabetes mellitus; GC: glycemic control; HC: hypercholesterolemic;
D: hemodialysis; HTG: hypertriglyceridemic; MA: microalbuminuria; NL: nor-
olipidemic; PD: peritoneal dialysis; SA: stable angina; SH: steatohepatitis; SIM:
imvastatin.
nd LDL minus based on its properties of electric mobility. After-
ards, Fabjan et al. showed that LDL modiﬁcations induced by
xidizing agents lead to the formation of LDL(−), as well as to par-
icles with higher degree of oxidation identiﬁed as LDL(2−), which
s more electronegative than LDL(−) [12]. Since then, more than
ne hundred of articles in the literature have assessed the role of
DL(−) in different chronic diseases and physiological conditions.
imilar to oxLDL, the LDL(−) content is increased in subjects with
amilial hypercholesterolemia [13–16], hypertriglyceridemia [13],
onalcoholic steatohepatitis [17], diabetes mellitus [18–22], and
oronary artery disease [23,24], in addition to patients undergo-
ng hemodialysis (HD) [25,26] and athletes after aerobic exercise
27,28] (Table 1). Despite the relevance of these results, the ori-
in and biochemical role of LDL(−) in health and disease is not yet
ompletely clear.
In this review, our aim was to evaluate the “state of the art” of
DL(−). Therefore, retrospective information on physicochemical,
nﬂammatory, and immune characteristics, such as effects of life
tyle (including diet, exercise) and drugs on modulation of LDL(−)
n different physiological and pathological processes, will be dis-
ussed.
. Physicochemical characteristics of LDL(−)
LDL(−) is a modiﬁed LDL sub-fraction present in vivo, which
as ﬁrst isolated by ion-exchange chromatography [1]. Usually,
he plasma concentration of this particle is lower than 10% of
otal LDL in healthy subjects, and greater than 10% of total LDL in
atients with high cardiovascular risk [13,14,16,22]. The mecha-
isms that explain the increase of LDL(−) generation in individuals
ith CHD are not entirely clear. According to Yologlu et al., it
s likely that the LDL particles in dyslipidemic subjects are more
rone to oxidation than in normolipidemic individuals. Therefore,tic protein-1; NEFA: non-esteriﬁed fatty acids; PAF-AH: platelet-activating factor
acetylhydrolase; PUFA: polyunsaturated fatty acids; TBARS: thiobarbituric acid-
reactive substances.
the presence of a large number of lipoprotein particles with pro-
inﬂammatorycapacitywouldcontribute toendothelial dysfunction
thus increasing the cardiovascular risk [33]. In this context, the
interaction of LDL(−) with endothelial cells promotes the release
of granulocyte/monocyte colony-stimulating factor (GM-CSF) that
contributes to increase foam cells formation, thus amplifying the
oxidative stress in the intima and changing the quality and compo-
sition of the extracellular matrix in the atheroma [34].
Differences in physicochemical properties, composition, and
oxidative parameters between native and electronegative LDL
could explain the atherogenic and inﬂammatory actions of this
particle (Table 2). LDL(−) has low levels of antioxidant vitamins
and a high content of oxidized cholesterol, lipoperoxides, conju-
gated dienes, and thiobarbituric acid reactive substance (TBARS)
[6,16,22,37]. LDL(−) fromsubjectswitheither familial hypercholes-
terolemia or normolipidemia is relatively rich in free cholesterol
and triglycerides, and itsApoBcontent is lower than that in thenon-
electronegative LDL fraction [14]. LDL(−) also contains increased
amounts of ApoE, ApoC-III, sialic acid, and non-esteriﬁed fatty acids
(NEFA) [14]. LDL(−) and-tocopherol levels showed an inverse and
signiﬁcant correlation [30]. Regarding lipid proﬁle, the percentage
of LDL(−) was positively correlated with LDL cholesterol [39].
Differently from in vitro oxidized LDL, LDL(−) particles show
altered structure of the surface lipids and a denatured ApoB-100
backbone that appears to be buried into the lipophilic environment
[11,37,40,41]. However, LDL(−) did not show ApoB fragmentation
or other changes arising from excessive oxidation. This observation
was conﬁrmed by our group,who found structuralmodiﬁcations in
ApoB of LDL(−) by circular dichroism spectroscopy [37]. According
to our previous results, LDL(−) recognized by anti-LDL(−) mon-
oclonal antibodies (clone 3D1036), shows a slight alterations of
secondary structure. In addition, it is well established that differ-
osclero
e
c
[
t
c
t
T
a
i
A
c
a
l
o
P
g
w
c
a
c
s
t
p
N
a
b
i
s
r
h
o
L
v
b
o
r
a
L
c
i
f
m
a
l
L
c
o
n
g
n
f
h
d
l
e
l
n
b
c
f
e
i
rA.P.Q. Mello et al. / Ather
nces in the lipid compositionof LDLpromoteApoB conformational
hanges that are relevant for LDL interaction with B/E receptor
42]. Binding of native LDL to its receptor is mediated by posi-
ively charged Lys residues in ApoB that have afﬁnity for negatively
harged Cys residues in the receptor binding domain. In con-
rast, LDL(−) has low binding afﬁnity for the LDL receptor [43].
he increased electronegativity and low number of active surface-
ccessible Lys residues in this particle certainly contributed to
ts decreased afﬁnity for the LDL receptor [35]. The unfolding of
poB-100 and its sinking into the particle surface lipids can also
ontribute for this effect [40]. In addition, interaction with PGs is
n essential step in the retention of LDL by subendothelial extracel-
ularmatrix, and it appears that this binding involves basic residues
f amino acids (ApoB) and negatively charged proteoglycans (PGs).
reviously, Borén et al. [44] developed a model based on muta-
enesis of the large ApoB protein to assess its functional domains
ithin native LDL. In short, recombinant LDL thus obtained showed
hances in lysine to glutamic acid (K3363E), basic to neutral amino
cids (RK3359-3369A) in site B, where arginine residues were
hanged to serine ones, and lysine to alanine or arginine was sub-
tituted with to glutamine (R3500Q). The same authors described
hat arginine at residue 3500 stabilizes the carboxyl terminus,
ermitting normal interaction between LDL and its receptor [45].
evertheless, only recombinant lysine (K3363E) LDL and lysine and
rginine (RK3359-3369A) LDL were associated with decreased PGs
inding [45]. Therefore, these amino acids residues appear to be
mportant for the atherogenic potential of LDL. Previously, it was
hown that native LDL has two lysine populations, i.e., “normal” Lys
esidues have a pKa of 10.4 whereas “active” Lys residues, which
ave been suggested to be involved in receptor binding, have a pKa
f 8.8 [43]. Interestingly, LDL(−) sub-fraction showeda third type of
ys residues, named “intermediate” Lys, with a different microen-
ironment and higher basicity (pKa 10.7) [43]. These differences
etween native LDL and LDL(−) indicate a distinct conformation
f ApoB-100 with a possible loss of afﬁnity of LDL(−) for the B/E
eceptor [43]. In fact, LDL(−) from subjects with normolipidemia
nd familial hypercholesterolemia shows impaired binding to the
DL receptor, a characteristic that could lead to decreased in vivo
learance of this particle [35]. Lower clearance of LDL(−) results in
ncreased residence time in blood circulation, which in turn could
avor furthermodiﬁcations of LDL(−) resulting in increased inﬂam-
atory and atherogenic potential.
As compared to native LDL, LDL(−) presents increased binding
fﬁnity to arterial PGs, the main component of the subendothe-
ial extracellular matrix. This property would favor retention of
DL(−) on the PG-rich surface layer of the arterial intima thus
ontributing to progression of atherosclerosis [36]. The interaction
ccurs between positively charged residues of ApoB-100 and the
egatively charged sulfate and carboxyl groups in the glycosamino-
lycan (GAG) chains of PGs [46,47]. Regarding that the negative
et charge of LDL(−) is a common characteristic in all LDL(−) sub-
ractions, their interactionwithPGs couldbedecreased.However, it
as been previously reported that the LDL(−) subpopulation shows
ifferent size, density, and composition that contributes to distinct
evels of binding to PGs [13,36].
In contrast to the oxidative origin of LDL(−), Sánchez-Quesada
t al. veriﬁed that both native and electronegative LDL present low
evels of lipid peroxidation products, an indication that LDL(−) is
ot only produced by oxidative modiﬁcation [48]. Physical and
iological characteristics of LDL(−) consist of nonenzymatic gly-
osylation, increased content and activity of platelet-activating
actor acetylhydrolase (PAF-AH) and phospholipase A2 (PLA2),
nrichment of NEFA, hemoglobin and ApoB-100 cross-linking, and
ncrease in ApoC-III and ApoE in LDL [48].
Glycation and oxidation of LDL reduces its afﬁnity for the LDL
eceptor, leading to reduced hepatic catabolism, increased con-sis 215 (2011) 257–265 259
tent of cholesteryl esters in macrophages, and altered endothelial
function [49]. These events seem to be closely interrelated. In addi-
tion, as a result of hyperglycemia, tissue and plasma proteins are
modiﬁed and their physiological function is disturbed [50]. Pro-
tein glycation that occurs in diabetic patients is regarded as one
of the key factors in the pathogenesis of diabetic complications,
including accelerated atherosclerosis [51]. Although nonenzymatic
glycosylation and oxidation are increased in type 2 diabetes (DM2),
these features would not be directly involved in the generation
of LDL(−) [22]. LDL(−) properties suggest that high content of
this particle in plasma could promote accelerated atherosclero-
sis in DM2 patients through both an increase in its residence
time in plasma and induction of an inﬂammatory response in
the arterial wall cells [22]. Optimization of glycemic control in
DM2 subjects increased native LDL resistance to oxidation (longer
lag-phase time) but no effect was observed in oxidizability of
LDL(−) [22]. In a recent study conducted in patients with DM2,
LDL(−) decreased signiﬁcantly as compared to baseline levels after
treatment with oral antidiabetic drugs (both pioglitazone and
metformin for 12 weeks), suggesting that hypoglycemic drugs
may have an antiatherosclerotic effect [52]. Previously, Sánchez-
Quesadaet al. [21]described thathigh level of glycation isnecessary
for LDL to achieve its electronegativity. These ﬁndings clearly show
that further physicochemical changes in LDL contribute to the gen-
eration of LDL(−). Therefore, events such as aggregation [36] and
high PAF-AH activity [21] contribute to the generation of LDL(−) by
an oxidative-independent mechanism. Nevertheless, LDL(−) from
diabetic patients shows inﬂammatory potential associated with
chemokine release in endothelial cells. This proatherogenic effect
could be related to the high PAF-AH activity observed in LDL(−)
[21].
The lipoprotein-associated phospholipase A2 (Lp-PLA2), also
known as PAF-AH, is considered a member of the group of phos-
pholipases A2, which are speciﬁc for hydrolysis of phospholipids
[53]. PAF-AH is produced by inﬂammatory cells and is mostly
transported by LDL (85%), where it hydrolyzes oxidized phos-
pholipids. Several studies propose a proinﬂammatory role for
PAF-AH that acts by forming noxious bioactive lipid mediators
(lysophosphatidylcholine and oxidized NEFA) in the lesion-prone
vasculature [54]. Asatryan et al. observed that LDL incubated with
low-molecular weight phospholipases A2 (PLA2) induced forma-
tion of LDL(−) without evidence of signiﬁcant increase in lipid
peroxidation [55]. The action of PAF-AH produces lysophospho-
lipids and mainly lysophosphatidylcholine (LPC) that links this
enzyme to early coronary atherosclerosis [56].Müller et al. showed
that presence of lysophosphatidylcholine implies that an addi-
tional way is available for the organism to modulate the intensity
of production of reactive oxygen species at the inﬂammatory site
[57]. Although increased PAF-AH activity appears to be strongly
related to high cardiovascular risk [58], this particle displays an
important role in the preventing additional oxidation of LDL(−)
[21], thus reinforcing the non-oxidative mechanism for the gener-
ation of LDL(−). Recently, we observed that obese adolescents have
increased PAF-AH activity, although it did not show correlation
with LDL(−) levels (unpublished data). These results are consis-
tent with the presence of other mechanisms contributing for the
generation of LDL(−).
In addition, Benítez et al. [35] observed that enrichment of LDL
with NEFA promotes a concentration-dependent loss of afﬁnity for
its receptor, although PLA2 treatment had been more effective in
generating LDL(−) than NEFA-induced modiﬁcation. In vitro mod-
iﬁcation of LDL by PLA2 or NEFA enhanced its electronegativity
and resulted in an increase in the lysophosphatidylcholine content
[34,35]. NEFA enrichment of LDL and apolipoprotein released by
lipolysis could also increase LDL electronegativity [48]. In humans,
increased NEFA content in LDL(−) from subjects with familial
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ypercholesterolemia and diabetes is likely to play a major role
n the loss of afﬁnity of LDL(−) for the LDL receptor [22].
In addition, Ziouzenkova et al. observed that high degree
f ApoB-100 modiﬁcation resulted from the formation of cova-
ent bond between hemoglobin (Hb) and LDL, which promoted
ormation of dityrosine but not malondialdehyde epitope [25]. Hb-
ediated reactions can be implicated in the oxidative stress that
rises during hemodialysis (HD). These modiﬁcations were prob-
bly induced by inﬂammatory processes occurring after contact
etween the blood and the HD membranes [25]. Hb-mediated oxi-
ation induces the formation of cross-linking between ApoB and
b backbones and increase in LDL electrophoretic mobility. These
eactions also yielded a marked dose-dependent increase in the
evels of LDL(−) and LDL(2−) with a preferential conversion to
DL(−), whereas the proportion of LDL(2−) was approximately
0 times lower than that of LDL(−) [25]. Interaction between
DL(−) and free Hb (total and metHb) promotes modiﬁcations in
poB and an increase in the negative net charge of LDL, although
ith not strong lipid oxidation of LDL (TBARS and hydroperox-
des). Therefore, modiﬁcation of LDL by Hb occurs through a lipid
eroxidation-independent mechanism [59]. These observations
ere recently reinforced after analysis of LDL(−) from patients
ndergoing hemodialysis. These subjects showed high levels of
DL(−) when compared with both patients undergoing peritoneal
ialysis and normal healthy individuals. On the other hand, most
ronounced lipid abnormalities were shown by patients undergo-
ng peritoneal dialysis [26,32].
Furthermore, recent evidence suggests that enrichment of LDL
ith ApoC-III contributes to the generation of electronegative,
roinﬂammatory and atherogenic particles, which are compatible
ith the properties of LDL(−) [60]. This possibility was reinforced
y Mauger et al. [61] who veriﬁed a strong correlation of ApoC-III1
nd ApoC-III2 with the small dense LDL phenotype. Recently, Mello
t al. [62] observed that LDL(−) is mainly associated with smaller
nddenser LDLparticles. Furthermore, Floodet al. [63],Hiukkaet al.
60] and Camejo et al. [46] proposed that interaction of modiﬁed
DL and small dense LDLwith PGs is inﬂuencedbyApoC-III. Regard-
ng the presence of sialic acid in LDL(−) it is likely that binding of
his particle to the arterial PGs depends on the degree of sialylation
f ApoC-III. However, recently Bancells et al. [64] showed that pres-
nce of ApoC-III and ApoE do not inﬂuence LDL(−) binding afﬁnity
or PGs.
In addition to the biochemical mechanisms described above,
édie et al. previously proposed that variations observed in the
enes coding for apolipoproteins (ApoB and ApoC-III) could change
he electrophoretic behavior of LDL [65]. As ApoB is the main struc-
ural apolipoprotein of LDL, variations in theApoBgene could result
n differences in the electric charge of this particle in individuals
ith similar LDL lipid proﬁle.
According to the response-to-retention hypothesis proposed by
illiams and Tabas [47,66], lipoprotein retention is a key event in
rovoking initial damage to the normal artery and thus promot-
ng atherosclerotic lesions. Regarding this hypothesis, retention
f LDL(−) could contribute to atherosclerotic process by differ-
nt mechanisms related to both the oxidative properties of the
article and modiﬁcation-induced conformational changes (size
nd density) affecting lipids and proteins [67]. Recently, Bancells
t al. [36] proposed that aggregation appears to cause increased
DL(−) binding afﬁnity to PGs favoring the retention of LDL(−). In
ddition, previous results support the idea that retained LDL(−)
ontributes to the development of atherosclerosis by different
ays, such as, apoptosis, inﬂammation, cytokines release and cyto-
oxicity [39,48].
Therefore, independently of the multiple and complex origin of
he LDL(−), its interaction with PGs is essential for its retention and
ts participation in the atherosclerotic process.sis 215 (2011) 257–265
3. Inﬂammatory and immune response
Both LDL oxidized in vitro by different agents and LDL(−)
show pro-inﬂammatory characteristics associated with immune
response activation. Presence of these modiﬁed lipoproteins in
the bloodstream stimulates components of the immune system
that are related to the acute and chronic phases of many diseases,
especially atherosclerosis. These biomarkers include macrophages,
T cells, monocyte chemotactic protein-1 (MCP-1), autoantibod-
ies and autoantigens related to modiﬁed lipoproteins, interleukins
(IL-1, IL-2, IL-6, IL-8, IL-12, and IL-10), tumor-necrosis factor
(TNF), gamma-interferon (-IFN), and platelet-derived growth fac-
tor [41,68–70]. This proﬁle is consistent with previous studies
conducted by Sanchéz-Quesada et al. [14] andDe Castellarnau et al.
[68], who observed that LDL(−) isolated from plasma of both nor-
molipidemic subjects and patients with FH has pro-inﬂammatory
actions.
Regarding the immune nature of atherosclerosis, adhesion of
monocytes to the arterial wall endothelium appears be one of the
key events in the early development of atherosclerotic plaques.
Frostegård et al. found a strong increase in the amount of adhe-
sion molecules adhered to endothelial cells after their exposure
to oxidized LDL (when compared to native LDL), suggesting that
oxLDL induces adhesion as well as monocyte differentiation [71].
In this context, Fukumoto et al. [72] and Shoji et al. [73] observed
that the immune system generates antibodies to oxLDL in pres-
ence of oxLDL. According to Inoue et al. [74], and Monaco et al. [75],
anti-oxLDLantibodies showadeleterious effect. Afterwards, Faviou
et al. [76] found that the concentration of anti-oxLDL antibodies in
patients with unstable or stable angina was higher than in healthy
subjects, reinforcing the idea of potential negative effect of these
antibodies. In contrary, Karvonen et al. [77] showed that autoan-
tibodies (IgM isotype) have an inverse association with carotid
atherosclerosis, suggesting that activation of the humoral immune
response to oxidized LDL may be beneﬁcial. Recently, Chou et al.
[78] described that oxidation-speciﬁc epitopes are themajor target
of natural antibodies.
Similarly to the proﬁle of oxLDL described above, LDL(−)
shows proinﬂammatory and immunogenic properties. According
to Siqueira et al. [79], there is growing experimental evidence
for the participation of acquired immunity in atherosclero-
sis. However, few studies link the immune response to oxLDL
and the cardiovascular risk conferred by the metabolic syn-
drome.
Using an animal model, we previously observed that diet sup-
plementation with soy isoﬂavones decreased the amount of IgG
autoantibodies reactive to LDL(−) as compared to the group with-
out supplementation. This event could be related to a lower
generation of LDL(−) and, consequently, lower stimulation of the
humoral immune response [80].
Further, after treating LDLr−/− mice with anti-LDL(−) mono-
clonal antibody (clone 31036), Grosso et al. [81] observed that
their levels of circulating free LDL(−) were lower than those in
either non-immunized mice or those immunized with irrelevant
monoclonal antibody. This indicates that passive immunization
with anti-LDL(−) monoclonal antibody had a protective effect
on atherosclerotic plaque development. It is possible that the
decreased levels of free LDL(−) in blood plasmawere due to the for-
mation of immune complexes between LDL(−) and themonoclonal
antibody injected into mice. If formation of immune complexes
had actually occurred, it could be concluded that the monoclonal
antibody neutralized the circulating LDL(−) particles and their
atherogenic and inﬂammatory effects were avoided. In addition,
the authors demonstrated that mice treated with the anti-LDL(−)
monoclonal antibody had less foam cells in the subintimal layer of
atherosclerotic lesions than the control mice.
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In subjects with CHD, Oliveira et al. [24] and Siqueira et al. [82]
ound that the titers of antibodies anti-LDL(−) were higher than in
hecontrol group.However, Barroset al. [83] foundanoppositepro-
le in children and adolescents. The concentration of anti-LDL(−)
utoantibodies in normocholesterolemic individuals was higher
han that in hypercholesterolemic subjects with or without family
istory of acute cardiovascular event.
In summary, LDL(−), as oxLDL, is able to activate inﬂamma-
ory and immune responses, but the real impact of anti-LDL(−)
utoantibodies in the atherosclerotic process andother chronic dis-
ases is not yet clear. Fig. 1 shows a possible mechanism that links
DL(−) and inﬂammatory and immune responses to atheroscle-
osis. According to this hypothesis, native LDL (nLDL) may either
e modiﬁed in blood plasma under inﬂammatory conditions or
igrate into the sub-endothelial space where it undergoes oxida-
ive and possibly other structural modiﬁcations that result in
DL(−). LDL(−) is internalized by macrophages through scavenger
eceptors generating foam cells. Further, epitopes from LDL(−) are
resented to B cells by macrophages and anti-LDL(−) antibod-
es are produced. After this step, immune complexes to LDL(−)
IC-LDL(−)] could precipitate and stimulate the maintenance of
he inﬂammatory and immune responses. In this condition, free
DL(−), antibodies to LDL(−), and IC-LDL(−) remain in the intima
nd can be effused to the lumen space. This view is compatiblewith
he presence and detection of these biomarkers in the lumen and
therosclerotic lesions.
. Pathophysiological properties of LDL(−)
LDL(−) is considered an important factor in the initiation and
rogression of atherosclerotic plaques. In vitro studies showed that
DL(−) in cultured endothelial cells has cytotoxic effect and stimu-
ates apoptosis andproductionof leukocyte recruitmentmediators,
uch as interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-
), and vascular cell adhesion molecule 1 (VCAM-1) [6,14,84].
The interaction of LDL(−) with endothelial cells and the con-
equent release of granulocyte/macrophage colony-stimulating
actor (GM-CSF) could contribute to increase the formation of foam
ells, both changing oxidative stress in the intima and the charac-
eristics and composition of extracellular matrix in atheromatous
laques [34]. The in vitro susceptibility of LDL to oxidative modiﬁ-
ation has been positively associated with the amount of LDL(−),
hich shows lipidperoxides, necessary to initiate copper-catalyzed
DL oxidation [85]. However, mechanisms independent of oxida-
ive modiﬁcations are able to generate LDL(−) with atherogenic
otential.
Besides the in vitro studies, considerable in vivo evidence has
hown that LDL(−) is present in plasma and atherosclerotic lesions
f humans [7], rabbits [8] and mouse [81].
De Castellarnau et al. [68] and Sánchez-Quesada et al. [14]
howed that LDL(−) isolated from either normocholesterolemic or
ypercholesterolemic subjects induced release of IL-8 and MCP-1
n endothelial cells, supporting the hypothesis that this particle is
roinﬂammatory and atherogenic in humans.
In type 1 and 2 diabetes mellitus (DM1 and DM2), LDL could
e differently modiﬁed. Whereas subjects with DM1 show a favor-
ble lipid proﬁle and presence ofmicroangiopathy, thosewithDM2
xhibit a proﬁle related to dyslipidemia andmacroangiopathy. This
roﬁle is reinforced by LDL analysis, in which LDL from subjects
ith DM1 shows the highest electrophoretic mobility, compatible
ith LDL(−) content; whereas differently, subjectswith DM2 show
DL(−) is in a state of higher susceptibility to oxidation and with
higher content of diene conjugates [86]. Moro et al. [18] studied
atients with DM2 and found that LDL was more glycated, more
usceptible to in vitro oxidation, and contained a higher percentage
f LDL(−)whencomparedwithnativeLDL.GlycationofApoB ispro-sis 215 (2011) 257–265 261
posed to be associated with a signiﬁcant increase in the production
of in vivo and in vitro oxidized LDL.
Sánchez-Quesada et al. [13] found that LDL(−) from nor-
mocholesterolemic individuals was predominant in the dense
sub-fraction (Phenotype B), whereas most of LDL(−) from patients
with familial hypercholesterolemia (FH) was present in the light
LDL subclasses (Phenotype A). It is likely that the differences
between contents of LDL sub-fractions found in this study reﬂect a
change in triglyceride content in these sub-fractions. A similar pro-
ﬁle was previously described by Sevanian et al. [85]. In contrast,
Chappey et al. [87] found a bimodal distribution, in which LDL(−)
was present in both denser and lighter LDL particles. The increase
in the production of LDL(−) is closely related to the increase in the
levels of oxLDL and small and dense LDL [31]. This observation is
reinforced by the association observed between negative charge in
LDL and inﬂammatory markers of atherosclerosis [14,88].
Regarding renal disease, the levels of LDL(−) in renal patients
undergoing dialysis are higher than in normal subjects. LDL(−)may
be a usefulmarker of oxidative stress, and Lobo et al. suggested that
patients undergoing hemodialysis are more susceptible to cardio-
vascular disease due to this condition [26].
Therefore, LDL(−) is a potential marker present in patho-
physiological processes related to cardiovascular disease, diabetes
mellitus, renal disease, and possibly other diseases.
5. Methods for detection of LDL(−)
Firstly, Avogaro et al. [1] isolated LDL(−) using anion-exchange
chromatography in a HPLC system, and this technique was later
optimized ina FPLC system[3,5,7,14]. Although thesemethodsgen-
erate semi-quantitative results, they remain the principal tool used
in studies on LDL(−).
In the late years, capillary isotachophoresis (cITP) has also
been used as a technique to characterize plasma lipoprotein sub-
fractions according to their net electric charges [89]. The cITP
technique allowed separation of two major LDL sub-fractions, fast-
(fLDL) and slow-migrating LDL (sLDL), according to their elec-
trophoretic mobilities. The fLDL fractions correspond to LDL(−),
-VLDL, and small dense LDL. After the light LDL fraction was pre-
cipitated from whole serum with heparin-Mg2+, electronegative
LDL could be measured using cITP in the small dense LDL fraction
[90,91]. Therefore, the analytical cITP technique may be useful in
the routine analysis of lipoprotein proﬁles. Itwas previously shown
that the absolute levels of lipoprotein sub-fractions can be deter-
minedas thepeakarea relative to that of an internalmarker, and the
levels of fLDLandsLDLwereproportional to theLDLprotein content
[91]. These authors reported that the fLDL and sLDL levels are asso-
ciatedwith thecarotid-artery intima-media thickness and that fLDL
is signiﬁcantly related to the level of serum triglycerides (TG). This
observation was previously demonstrated by Sánchez-Quesada
et al. [13], who reported that patients with hypertriglyceridemia
have an increased proportion of LDL(−). Therefore, high levels of
TG could contribute to increased LDL electronegativity. Difﬁculties
due to lack of standardized assays to measure circulating LDL(−)
have been overcome by the development of monoclonal antibod-
ies (MAb 3D1036) [37]. Our laboratory has developed an assay to
measure LDL(−) in plasma, total LDL and LDL sub-fractions and tis-
sues using a monoclonal antibody MAb (3D1036) that recognizes
epitopes in LDL(−) but not in native LDL (cross-linking <1.0%).
Recently, Faulin et al. [92] developed and validated a sandwich
enzyme-linked immunosorbent assay (ELISA) to measure LDL(−)
in human plasma using two different monoclonal antibodies (free
and biotinylated, MAb-1A3 and MAb-2C7, respectively).
Regarding use of antibody (in comparison with other tech-
niques), its main advantages are (I) speciﬁcity and sensitivity, (II)
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aig. 1. Immune and cellular mechanisms involving electronegative low-density lip
DL(−), IL-1: interleukin-1, LDL(−): electronegative LDL, MHC: major histocompat
NF: tumor-necrosis factor, and -IFN: gamma-interferon. For more information, p
imultaneous analysis of large number of samples, (III) reduced
ime of analysis per sample, and (IV) direct detection in different
iological ﬂuids.
Therefore, theELISA technique is a verypractical tool tomeasure
DL(−) in human blood for both widespread research and clinical
iagnosis.
The current methods used to monitor LDL(−) are speciﬁc for
lectronegative LDL independently of its origin. These methods are
ot able to discriminate LDL(−) generated by non-enzymatic gly-
osylation, increased expression and activity of platelet-activating
actor acetylhydrolase (PAF-AH) and phospholipase A2 (PLA2),
nriched NEFA, hemoglobin and ApoB-100 cross-linking, increase
n ApoC-III and ApoE or oxidation reactions in LDL. In addi-
ion,while chromatographic and electrophoreticmethods evaluate
otal LDL(−) particle regarding its electronegativity, ELISA (based
n monoclonal antibodies – MAb) utilizes FPLC-puriﬁed human
DL(−) which is used as antigen to generate the MAbs [37]. These
Abs recognize epitopes presents in LDL(−) that was also isolated
s a function of its net electric charge.
Although most studies show increased levels of LDL(−) in sub-
ects with high cardiovascular risk, previously Barros et al. [83] and
órdoba-Porras et al. [93] did not show signiﬁcant differences rela-
ive to controls. These differences are probably associated with the
istinct design of the studies, in which clinical and demographic
haracteristics of subjects are a crucial point. Current studies in the
iterature are limited to a reduced number of subjects (n<100), and
istinct methods of detection. In addition, there are few validation
nd reproducible studies.
. Effect of drugs and life styleFrom the classical studies conducted by Anitschkow (1913) on
iet and cardiovascular disease [94], it is accepted that compo-
ents of the diet are important in the development, prevention,
nd treatmentof cardiovascular diseases.Whereas cholesterol [95],ein [LDL(−)]. Anti-LDL(−): antibodies to LDL(−), IC-LDL(−): immune complexes to
complex, M: macrophages, M/Th1: activated macrophages, nLDL: native LDL,
see text.
the saturated and trans fatty acids stimulate the atherogenic pro-
cess [96], consumption of ﬁber and monounsaturated (w-9) and
polyunsaturated fatty acids (w-3 andw-6) [97–100]modulate lipid
metabolism and reduce the cardiovascular risk. Besides the well-
established role of the nutrients describe above, involvement of
isolated soy protein [101,102], isoﬂavones [8], phenolic compo-
nents [103], phytosterols [104], and antioxidants [105–107] has
shown that other diet components display important effects on
the development of atherosclerosis and other diseases in which
modiﬁcation of LDL is present.
Soy isoﬂavones can both prevent lipid peroxidation by scaveng-
ing lipid-derived peroxyl radicals and inhibit copper-dependent
LDL oxidation [108,109]. Damasceno et al. [80] observed that
isoﬂavones decreased the amount of LDL(−) in plasma and aorta
of dyslipidemic rabbits. This effect occurred for both high and low
intake of isoﬂavones (7.3 and 0.73mg/kg of body per day, respec-
tively), butwithdifferent intensity. Previously,Wisemanet al. [110]
reported that isoﬂavone-containing soy protein is more effective
in inhibiting LDL oxidation than isoﬂavone-depleted soy protein.
Similarly, Damasceno et al. [102] worked with rabbits and veriﬁed
that consumption of a diet rich in cholesterol and casein caused
an increase in the atherosclerotic lesion size in the aorta when
compared to animals that received a hypercholesterolemic diet
containing soy protein instead of casein. This increase observed in
the casein group may be associated with an increase in the gener-
ation of LDL(−).
In addition, Natella et al. [111] reported that supplementa-
tion with selenium for a 10-day period was able to prevent both
the postprandial increase in LDL(−) and susceptibility to oxidative
modiﬁcation in LDL. In another study, experimental data showed a
postprandial increase in LDL(−) concentration after ingestion of a
meal containing oxidizable lipids [112].
In vitro studies have shown that phenolic components present
in coffee are able to modify lipoprotein oxidative susceptibility. In
2007, it was observed that resistance of LDL to oxidative modi-
ﬁcation signiﬁcantly increased and LDL(−) concentration did not
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hange after coffee drinking. It is likely that these results indicate
ncorporation of coffee’s phenolic acids into LDL particles [113].
Regarding the antioxidant potential of nutrients and the
ioactive components present in diet, -tocopherol is the most
nvestigated of them. It is considered a chief antioxidant for the
revention of experimental atherosclerosis. It acts as a scavenger
f lipid peroxyl radicals in lipoproteins protecting them against
xidation and avoiding generation of oxLDL [114]. The effect of
-tocopherol supplementation on LDL(−) content in hemodialysis
HD) patients was previously investigated by Mafra et al. [32] who
bserved decreased LDL(−) levels after supplementation. On the
ther hand, Pereira et al. [29] observed that simvastatin decreased
DL(−) levels independent of its association with -tocopherol,
uggesting that-tocopherol does not affect the antioxidant action
f simvastatin in terms of protein nitration or generation of LDL(−)
n hypercholesterolemic subjects.
In fact, simvastatin therapy induced a progressive decrease in
he proportion of LDL(−). Simvastatin not only decreases plasma
holesterol but also modiﬁes the qualitative characteristics of LDL,
.g., improvementof LDL(−) afﬁnity for LDL receptor and increase in
ight LDL in comparison with dense LDL [115]. A similar proﬁle was
escribed by Zhang et al. [90], who evaluated low-dose rosuvas-
atin showing that this drug reduced LDL(−) content and the small
nd dense LDL sub-fractions in hypercholesterolemic patientswith
HD. Although reduction in the content of modiﬁed LDL may rep-
esent a novel pleiotropic effect of rosuvastatin, the mechanism
f these effects is not yet clear. These authors propose that up-
egulation in the number of LDL receptors is due to inhibition of
ellular cholesterol synthesis in patients under statin therapy. Sim-
larly, simvastatin therapy has been shown to increase the afﬁnity
f LDL(−) for LDL receptors in patients with familial hypercholes-
erolemia [16].
Recently, Tang et al. [116] evaluated the effect of LDL(−) from
mokers ondifferentiation of endothelial progenitor cells (EPC) and
bserved that themost electronegative fraction (L5)was associated
ith upregulation of lectin-like oxLDL receptor 1 (LOX-1 receptor)
nd inhibition of EPC.
Besides the effect of diet and drugs, the protective role of regular
xercise against atherosclerosis iswell established.However, infor-
ation on the effect of exercise on LDL(−) is insufﬁcient. According
o Sánchez-Quesada et al. [117], high levels of HDL in trained sub-
ects could explain the increased resistance of LDL to oxidation and
ecreased generation of LDL(−) observed in these subjects. This
ossibility was reinforced by a study conducted by Benítez et al.
28], in which high levels of HDL were related to reduced LDL oxi-
ation (approximately 20%). In athletes, however, LDL(−) content
fter aerobic exercise was higher than before [27,28]. According to
utteridge, intense exercise promotes an increase in O2 consump-
ion in skeletal muscle and this event favors oxidative modiﬁcation
f LDL [118].
Therefore, drugs and life style components (diet, smoke, and
xercise) are able to modify LDL(−) generation, possibly reducing
he cardiovascular risk.
. Conclusion
Classical risk factors for CHD include levels of total- (TC) and
DL cholesterol (LDL(−)C), low levels of HDL cholesterol (HDL-C),
swell as elevatedbloodpressure, smokinghabit, age, and recently,
besity, familial history of premature CHD, and physical inactivity.Currently, news risk factors were added to these parameters.
ualitative characteristics of lipoproteins, such as physicochemi-
al properties (size, electrophoretic mobility) and oxidative proﬁle,
ave been the goal of many studies. In this context, LDL(−) is a
otential marker. In this review, the major points focusing thissis 215 (2011) 257–265 263
particle showed that:
(I) Origin of LDL(−) is multiple and complex, and includes the
oxidative process;
(II) LDL(−) is able to activate the inﬂammatory and immune
responses;
III) Currently, no accessible commercial “gold standard” method is
available to evaluate LDL(−), and there is not any study showing
correlation between methods;
IV) Although LDL(−) is present in health and disease, its content
during pathological processes is higher than 10% of total LDL;
(V) Drugs, diet, cigarette smoking, and exercise modify the content
of LDL(−) in humans;
In conclusion, LDL(−) is a potential metabolic stress biomarker,
which is present in health and disease. Regarding the open prob-
lems relative to this particle, we propose that evaluation of LDL(−)
be included in prospective, randomized, and crossover trials, since
onlywith large-scale information its clinical relevancewill be safely
analyzed.
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